Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Net Income (2016 - 2026)

Champions Oncology has reported Net Income over the past 17 years, most recently at -$279000.0 for Q1 2026.

  • For Q1 2026, Net Income fell 106.21% year-over-year to -$279000.0; the TTM value through Jan 2026 reached -$2.3 million, down 136.46%, while the annual FY2025 figure was $4.7 million, 164.61% up from the prior year.
  • Net Income for Q1 2026 was -$279000.0 at Champions Oncology, down from $237000.0 in the prior quarter.
  • Over five years, Net Income peaked at $4.5 million in Q1 2025 and troughed at -$2.6 million in Q3 2023.
  • A 5-year average of -$469117.6 and a median of -$319000.0 in 2022 define the central range for Net Income.
  • Biggest five-year swings in Net Income: crashed 12843.75% in 2023 and later skyrocketed 277.67% in 2025.
  • Year by year, Net Income stood at -$16000.0 in 2022, then crashed by 12843.75% to -$2.1 million in 2023, then surged by 135.15% to $728000.0 in 2024, then tumbled by 67.45% to $237000.0 in 2025, then plummeted by 217.72% to -$279000.0 in 2026.
  • Business Quant data shows Net Income for CSBR at -$279000.0 in Q1 2026, $237000.0 in Q4 2025, and -$466000.0 in Q3 2025.